Read by QxMD icon Read

Hormone sensitive prostate cancer

Anikó Maráz, Lajos Géczi, Zsófia Küronya
During the last decades androgen deprivation therapy (ADT) was the standard treatment of prostate cancers. Survival of metastatic patients is 4 years if they receive ADT, but in case of poor prognosis survival rate is under 3 years. Since 2014 two prospective phase III studies have proven the survival advantage of early docetaxel therapy, administered together with ADT, for metastatic hormone-sensitive prostate cancer patients. Its advantage was even more considerable in case of high-volume metastatic cases...
March 19, 2019: Magyar Onkologia
Sarah Alessi, Paola Pricolo, Paul Summers, Marco Femia, Elena Tagliabue, Giuseppe Renne, Roberto Bianchi, Gennaro Musi, Ottavio De Cobelli, Barbara Alicja Jereczek-Fossa, Massimo Bellomi, Giuseppe Petralia
OBJECTIVES: To evaluate whether low PI-RADS v2 assessment categories are effective at excluding extraprostatic extension (EPE) of prostate cancer (≥pT3a PCa). METHODS: The local institutional ethics committee approved this retrospective analysis of 301 consecutive PCa patients. Patients were classified as low- or intermediate/high-risk based on clinical parameters and underwent pre-surgical multiparametric magnetic resonance imaging. A PI-RADS v2 assessment category and ESUR EPE score were assigned for each lesion by two readers working in consensus...
March 18, 2019: European Radiology
Igor Tsaur, Isabel Heidegger, Alexander Kretschmer, Hendrik Borgmann, Giorgio Gandaglia, Alberto Briganti, Pieter de Visschere, Romain Mathieu, Massimo Valerio, Roderick van den Bergh, Piet Ost, Cristian Mirvald, Derya Tilki, Guillaume Ploussard, Cristian Surcel
Recently, adoption of novel drugs for systemic treatment of metastatic prostate cancer has led to a striking improvement of response rate and survival in both hormone-sensitive and castration-resistant disease. In most cases, prostate cancer essentially depends on androgen receptor signaling axis, even in castration-resistant setting, and hence may be targeted by second generation hormonal therapy. However, a subset of patients bears androgen-independent cancer biology with a short-term response to hormonal treatment, early and extensive visceral metastases, low PSA levels and poor outcomes...
March 11, 2019: Cancer Treatment Reviews
(no author information available yet)
In men with metastatic hormone-sensitive prostate cancer, the androgen-receptor inhibitor enzalutamide prolonged radiographic progression-free survival more than a placebo did when given with androgen-deprivation therapy.
March 14, 2019: Cancer Discovery
Peter B Østergren, Klara K Ternov, Christian F S Jensen, Henrik Jakobsen, Henriette Lindberg, Jens Sønksen, Mikkel Fode
OBJECTIVES: Recent landmark studies (GETUG-AFU 15, CHAARTED, STAMPEDE (docetaxel), LATITUDE and STAMPEDE (abiraterone)) have changed the treatment of hormone sensitive metastatic prostate cancer (mHSPC) from androgen deprivation therapy (ADT) only to combined therapy with either docetaxelor abiraterone acetate plus prednisone (AAP) together with ADT. In this Review we highlight current evidence and recommendations on how to treat men with newly diagnosed mHSPC beyond ADTMETHODS: Narrative overview of available evidence retrieved from pubmed searches, hand searches and authoritative texts...
March 2019: Archivos Españoles de Urología
Samir D Mehta, Ronnie Sebro
PURPOSE: Dual-energy X-ray absorptiometry (DEXA) studies are used for screening patients for low bone mineral density (BMD). Patients with breast and prostate cancer are often treated with hormone-altering drugs that result in low BMD. These patients may have incidental osteoblastic metastases of the spine that may be detected on screening DEXA studies. The aim of this pilot study is to assess whether random forest classifiers or support vector machines can identify patients with incidental osteoblastic metastases of the spine from screening DEXA studies and to evaluate which technique is better...
March 9, 2019: International Journal of Computer Assisted Radiology and Surgery
Pedro Nazareth Aguiar, Pui San Tan, Sarah Simko, Carmelia Maria Noia Barreto, Bárbara de Souza Gutierres, Auro Del Giglio, Gilberto de Lima Lopes
OBJECTIVE: To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. METHODS: We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. RESULTS: Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0...
March 7, 2019: Einstein
José A Cordero, Gemma Sancho, Xavier Bonfill
PURPOSE: To estimate the use of intermittent androgen deprivation (IAD) therapy in patients with prostate cancer (PCa). METHODS: Retrospective, non-interventional study based on electronic pharmacy dispensation data of luteinizing hormone-releasing hormone (LHRH) analogs and anti-androgens in Catalonia (Spain). Intermittency was defined as the percentage of time off treatment (%IAD), which was calculated for the whole sample by dividing the sum of all off-IAD periods by the total time on any LHRH analog regimen...
March 6, 2019: Pharmacoepidemiology and Drug Safety
Sarah Burdett, Liselotte M Boevé, Fiona C Ingleby, David J Fisher, Larysa H Rydzewska, Claire L Vale, George van Andel, Noel W Clarke, Maarten C Hulshof, Nicholas D James, Christopher C Parker, Mahesh K Parmar, Christopher J Sweeney, Matthew R Sydes, Bertrand Tombal, Paul C Verhagen, Jayne F Tierney
BACKGROUND: Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). OBJECTIVE: To systematically review trials of prostate radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: Using a prospective framework (framework for adaptive meta-analysis [FAME]), we prespecified methods before any trial results were known. We searched extensively for eligible trials and asked investigators when results would be available...
February 27, 2019: European Urology
Xueli Wang, Mei Qi, Jing Zhang, Xiubin Sun, Hongwei Guo, Yu Pang, Qian Zhang, Xinyi Chen, Ruifeng Zhang, Zhiyan Liu, Long Liu, Xiaomeng Hao, Bo Han
OBJECTIVES: The predictive value of the histological parameters and molecular markers for neoadjuvant hormonal therapy (NHT) in prostate cancer (PCa) has not been well established. The aim of this study is to determine pathological variables that can predict differences in response to NHT in PCa. METHODS: A total of 85 locally high risk PCa patients with matched preoperative needle biopsies and radical prostatectomy (RP) specimens were included. All patients were treated with NHT for at least 3 months...
March 2, 2019: Prostate
Takayuki Arai, Satoko Kojima, Yasutaka Yamada, Sho Sugawara, Mayuko Kato, Kazuto Yamazaki, Yukio Naya, Tomohiko Ichikawa, Naohiko Seki
OBJECTIVES: To identify oncogenes regulated by micro-ribonucleic acid, miR-199a/b-3p, in metastatic castration-resistant prostate cancer. METHODS: Advanced ribonucleic acid sequencing technologies were applied to construct a micro-ribonucleic acid expression signature using metastatic castration-resistant prostate cancer autopsy specimens. Ectopic expression of mature micro-ribonucleic acids or small-interfering ribonucleic acids were applied to functional assays for cancer cell lines...
February 28, 2019: International Journal of Urology: Official Journal of the Japanese Urological Association
Mercedes Marín-Aguilera, Òscar Reig, Maria Milà-Guasch, Albert Font, Montserrat Domènech, Alejo Rodríguez-Vida, Joan Carles, Cristina Suárez, Aránzazu González Del Alba, Natalia Jiménez, Iván Victoria, Núria Sala-González, Maria José Ribal, Sandra López, Olatz Etxaniz, Geòrgia Anguera, Pablo Maroto, Pedro Luis Fernández, Aleix Prat, Begoña Mellado
TMPRSS2-ERG expression in blood has been correlated with low docetaxel benefit in metastatic castration-resistant prostate cancer (mCRPC). This multicenter study aimed to prospectively asses its role as a taxane-resistance biomarker in blood and retrospectively in tumors, exploring also the impact of prior abiraterone/enzalutamide (A/E) in patients and in vitro. TMPRSS2-ERG was tested by quantitative reverse-transcription PCR. We included 204 patients (137 blood and 124 tumor samples) treated with taxanes. TMPRSS2-ERG expression was correlated with prostate-specific antigen (PSA)-progression-free survival (PFS), radiological-PFS (RX-PFS), and overall survival (OS)...
February 26, 2019: International Journal of Cancer. Journal International du Cancer
Jeffrey Shevach, Matthew R Sydes, Maha Hussain
CONTEXT: Androgen deprivation therapy (ADT) is the standard of care for men with metastatic hormone-sensitive prostate cancer (HSPC) and a potential treatment option in those with prostate-specific antigen relapse after local therapy. Based on promising biological and preclinical data, several clinical trials compared the efficacy of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) with the objective of delaying disease progression and improving survival and quality of life (QoL)...
February 22, 2019: European Urology Focus
Masaki Shiota, Shintaro Narita, Shusuke Akamatsu, Naohiro Fujimoto, Takayuki Sumiyoshi, Maki Fujiwara, Takeshi Uchiumi, Tomonori Habuchi, Osamu Ogawa, Masatoshi Eto
Importance: Recently, genetic polymorphism in HSD3B1 encoding 3β-hydroxysteroid dehydrogenase-1 has been shown to be associated with oncological outcome when treated with androgen-deprivation therapy (ADT) for prostate cancer. Upfront abiraterone combined with ADT has proved survival benefit. However, its effect on oncological outcome among different ethnicities and in abiraterone treatment remain unclear. Objective: To investigate the significance of missense polymorphism in HSD3B1 gene among men treated with primary ADT or abiraterone...
February 1, 2019: JAMA Network Open
Maruša Turk, Urban Simoncic, Alison Roth, Damijan Valentinuzzi, Robert Jeraj
Metastatic cancer patients invariably develop treatment resistance. Different levels of resistance lead to observed heterogeneity in treatment response. The main goal was to evaluate treatment response heterogeneity with computation model simulating dynamics of drug-sensitive and drug-resistant cells. Model parameters included proliferation, drug induced death, transition and proportion of intrinsically resistant cells. Model was benchmarked with imaging metric extracted from 39 metastatic prostate cancer patients who had 18F-NaF-PET/CT scans performed at baseline and three cycles into chemotherapy or hormonal therapy...
February 21, 2019: Physics in Medicine and Biology
Iacopo Gesmundo, Laura Di Blasio, Dana Banfi, Tania Villanova, Alessandro Fanciulli, Enrica Favaro, Giacomo Gamba, Chiara Musuraca, Ida Rapa, Marco Volante, Stefania Munegato, Mauro Papotti, Paolo Gontero, Luca Primo, Ezio Ghigo, Riccarda Granata
Prostate cancer (PCa) is one of the most common cancer in men. Although hormone-sensitive PCa responds to androgen-deprivation, there are no effective therapies for castration-resistant PCa. It has been recently suggested that proton pump inhibitors (PPIs) may increase the risk of certain cancers; however, association with PCa remains elusive. Here, we evaluated the tumorigenic activities of PPIs in vitro, in PCa cell lines and epithelial cells from benign prostatic hyperplasia (BPH) and in vivo, in PCa mice xenografts...
February 18, 2019: Cancer Letters
Tyler Etheridge, Shivashankar Damodaran, Adam Schultz, Kyle A Richards, Joseph Gawdzik, Bing Yang, Vincent Cryns, David F Jarrard
Androgen deprivation therapy (ADT) has been the standard of care for the last 75 years in metastatic hormone sensitive prostate cancer (PCa). However, this approach is rarely curative. Recent clinical trials have demonstrated that ADT combined with other agents, notably docetaxel and abiraterone, lead to improved survival. The mechanisms surrounding this improved cancer outcomes are incompletely defined. The response of cancer cells to ADT includes apoptosis and cell death, but a significant fraction remains viable...
January 2019: Asian Journal of Urology
Andrew W Hahn, David D Stenehjem, Anitha B Alex, David M Gill, Heather H Cheng, Elizabeth R Kessler, Namita Chittoria, Przemyslaw Twardowski, Ulka Vaishampayan, Neeraj Agarwal
PURPOSE: Contemporary treatment for metastatic hormone sensitive prostate cancer (mHSPC) includes androgen deprivation therapy (ADT) plus abiraterone or docetaxel. While these intensified regimens have improved efficacy, they are also associated with increased cost and toxicities. Not all men with mHSPC may be candidates for these intensified regimens, yet there are no clinical models or biomarkers used to optimize treatment selection. Herein, we hypothesized that longer time from prior definitive therapy (DT), either radical prostatectomy, definitive radiotherapy, or both, to onset of metastatic disease is associated with improved survival outcomes in men with newly diagnosed mHSPC...
February 13, 2019: Urologic Oncology
F Hall, H M de Freitas, C Kerr, T Ito, B Nafees, A J Lloyd, J Penton, M Hadi, S Lanar, T P Pham
PURPOSE: To capture UK societal health utility values for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and the disutility associated with treatment-related adverse events (AEs) to inform future cost-utility analyses. METHODS: A literature review, and patient and clinical expert interviews informed the development of health states characterising mHSPC symptoms and the impact of treatment-related AEs on health-related quality of life (HRQL). Three base health states were developed describing a typical patient with high-risk mHSPC: receiving androgen deprivation therapy (ADT) [Base State 1]; receiving docetaxel plus ADT [Base State 2]; completed docetaxel and still receiving ADT whose disease has not yet progressed [Base State 3]...
February 14, 2019: Quality of Life Research
Niranjan J Sathianathen, Yiannis A Philippou, Gretchen M Kuntz, Badrinath R Konety, Shilpa Gupta, Alastair D Lamb, Philipp Dahm
OBJECTIVES: Androgen deprivation therapy (ADT) has historically been the main management option for men with metastatic, hormone-sensitive prostate cancer. Over the last two decades, a number of agents have demonstrated a benefit in castration-resistant disease[1] and there has been interest to employ these drugs earlier in the disease course when the cancer is hormone-sensitive. Taxane-based chemotherapy has been utilized in such a manner and we aimed to assess the effects of early taxane-based chemohormonal therapy for newly diagnosed, metastatic, hormone-sensitive prostate cancer...
February 14, 2019: BJU International
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"